Skip Navigation LinksHome > January/February 2014 - Volume 38 - Issue 1 > Midtreatment Evaluation of Lymphoma Response to Chemotherapy...
Journal of Computer Assisted Tomography:
doi: 10.1097/RCT.0b013e3182a90ee7
Abdominal Imaging

Midtreatment Evaluation of Lymphoma Response to Chemotherapy by Volume Perfusion Computed Tomography

Spira, Daniel MD*; Grünwald, Leonard*; Vogel, Wichard MD; Sauter, Alexander MD*; Spira, Sven Michael MSc; Claussen, Claus Detlef MD*; Horger, Marius MD*

Collapse Box


Objective: The aim of this study was to search for chemotherapy-induced perfusion changes of diffuse large B-cell lymphoma, follicular lymphoma, and Hodgkin lymphoma at midtreatment versus baseline volume perfusion computed tomography (VPCT).

Methods: Forty-five consecutive patients with untreated diffuse large B-cell lymphoma, follicular lymphoma, and Hodgkin lymphoma received VPCT examinations of the tumor bulk at baseline and during chemotherapy (midtreatment). Blood flow (BF), blood volume (BV), and transit constant (K-trans) were determined. Treatment response was categorized according to the Cheson criteria into complete or partial remission and stable or relapsed/progressive disease.

Results: Midtreatment follow-up showed a reduction in BF, BV, and K-trans in all lymphoma subtypes compared with baseline. The reduction in BV was less pronounced in larger tumors. Notably, BF, BV, and K-trans decreased in the responders (complete remission/partial remission) when compared with the nonresponders (stable or relapsed/progressive disease). Less than 10% reduction in BF was shown to be the best VPCT criterion for the identification of nonresponse.

Conclusions: Chemotherapy-induced perfusion changes in responders are recognizable at midtreatment VPCT.

© 2014 by Lippincott Williams & Wilkins



Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.